Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.
PHILADELPHIA (February 22, 2021)—Kristen D. Whitaker, MD, MS, assistant professor in the Department of Clinical Genetics at Fox Chase Cancer Center, recently received a grant from the V Foundation for Cancer Research to study ways of improving diversity in clinical cancer trials. The grant was funded by Hooters of America, LLC.
PHILADELPHIA (February 19, 2021)—The Fox Chase-Temple University Hospital Department of Bone Marrow Transplant (BMT) and Cellular Therapies has achieved the top performance category in successful transplant procedures, making it the second year in a row that the center has earned this distinction.
PHILADELPHIA (February 15, 2021) – Researchers at Fox Chase Cancer Center have helped to identify a cellular resilience mechanism through which acute myeloid leukemia (AML) cells survive cancer treatment and repopulate leukemia, causing disease relapse. The research also suggests that certain drugs could be used to destroy these treatment-surviving AML cells.
PHILADELPHIA (February 2, 2021) – New research out of Fox Chase Cancer Center has shed light on how an important type of T cell–gamma delta T cells–develop and are assigned their effector function.
PHILADELPHIA (February 1, 2021)—Fox Chase Cancer Center will host a virtual symposium on cancer epigenetics on March 2 that will explore discoveries related to epigenetic mechanisms of tumorigenesis and novel therapies to better target cancer.
PHILADELPHIA (January 19, 2021)—Elizabeth Plimack, MD, MS, professor in the Department of Hematology/Oncology and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been appointed chair of the Scientific Advisory Board (SAB) for the Bladder Cancer Advocacy Network (BCAN).
PHILADELPHIA (January 11, 2021) – Fox Chase Cancer Center is pleased to announce the addition of Joel Helmke, MSHP, FACHE, to its senior leadership team as chief operating officer (COO). Helmke’s tenure will begin on February 1, 2021.
